Remarkably, the nanotoxin treatment presented no effect on the primary tumor, suggesting that T22-DITOX-H6 is capable of selectively eliminating the CXCR4-overexpressing cells responsible for the metastatic process. The gene discussed is CXCR4; the disease is neoplasm.